Research programme: pancoronavirus inhibitors - Orthogon Therapeutics
Latest Information Update: 03 Nov 2022
At a glance
- Originator Orthogon Therapeutics
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Coronavirus infections
Most Recent Events
- 26 Sep 2022 Early research in Coronavirus infections in USA (unspecified route), before September 2022 (Orthogon Therapeutics pipeline, September 2022)